<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952156</url>
  </required_header>
  <id_info>
    <org_study_id>HMI-102-101</org_study_id>
    <nct_id>NCT03952156</nct_id>
  </id_info>
  <brief_title>Gene Therapy Clinical Study in Adult PKU</brief_title>
  <acronym>pheNIX</acronym>
  <official_title>A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Homology Medicines, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Homology Medicines, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, randomized, concurrently-controlled, dose escalation study
      to evaluate the safety and efficacy of HMI-102 in adult PKU subjects with PAH deficiency.
      Participants will receive a single administration of HMI-102 and will be followed for safety
      and efficacy for 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of HMI-102 gene therapy in adult subjects
      with PKU due to PAH deficiency. Subjects will receive a single dose of HMI-102 administered
      intravenously. Up to 3 dose levels of HMI-102 may be investigated in this study. At a given
      dose level, a minimum of 2 subjects will be enrolled and dosed. Dosing of the first two
      subjects will be staggered. Following evaluation of data from the first 2 subjects in a
      cohort, a decision can be made to either escalate to the next dose level or expand the cohort
      at the selected dose level. If the cohort is expanded, additional subjects will be randomized
      to receive HMI-102 or a concurrent delayed treatment control arm. Subjects in the delayed
      treatment control will be eligible to receive HMI-102 after 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAE) and serious TEAEs</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Subjects with at least one TEAE or serious TEAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of sustained plasma Phe concentration of ≤360 μmol/L at 24 weeks post dose</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Subjects achieving a sustained plasma Phe concentration ≤360 μmol/L at 24 weeks post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Phe Concentration</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Change in plasma Phe concentration at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of achieving a plasma Phe concentration to ≤360 μmol/L</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Subjects achieving plasma Phe concentration ≤360 μmol/L at each time point during the study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Phenylketonuria Quality of Life Questionnaire (PKU-QOL)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Change in PKU-QOL</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Phenylketonurias</condition>
  <condition>PAH Deficiency</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 1 of HMI-102 delivered intravenously one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 2 of HMI-102 delivered intravenously one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 3 of HMI-102 delivered intravenously one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Treatment Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control subjects will generally have the same assessments as treated subjects. Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>HMI-102</intervention_name>
    <description>HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Adults 18-55 years of age at the time of informed consent

          -  Diagnosis of classic phenylketonuria (PKU) due to PAH deficiency

          -  Two plasma Phe values with a concentration of ≥ 600 μmol/L drawn at least 48 hours
             apart during the screening period and at least one historical value ≥ 600 μmol/L in
             the preceding 12 month.

          -  Subject has the ability and willingness to maintain their baseline diet, whether
             Phe-restricted or unrestricted, after administration of HMI-102, unless otherwise
             directed

        Key Exclusion Criteria:

          -  Subjects with PKU that is not due to PAH deficiency

          -  Presence of anti-AAVHSC15 neutralizing antibody

          -  ALT &gt;1.5x ULN and AST &gt;1.5x ULN

          -  Alkaline phosphatase &gt;1.5x ULN.

          -  Total bilirubin &gt;1.5x ULN, direct bilirubin ≥ 1.5x ULN

          -  Serum creatinine &gt;1.5x ULN

          -  Hematology values outside of the normal range (hemoglobin &lt;11.0 g/dL for males or
             &lt;10.0 g/dL for females; white blood cells (WBC) &lt;3,000/μL; absolute neutrophils
             &lt;1500/μL; platelets &lt;100,000/μL)

          -  Hemoglobin A1c &gt;7.9% or fasting glucose &gt;200 mg/dL

          -  Any clinically significant abnormal laboratory result at screening, in the opinion of
             the Investigator

          -  Contraindication to corticosteroid use or conditions that could worsen in the presence
             of corticosteroids, as assessed and determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Steven Glyman, M.D.</last_name>
    <phone>781-819-0967</phone>
    <email>clinicaltrials@homologymedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor Botha</last_name>
      <phone>404-778-8517</phone>
      <email>egeller@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Ries</last_name>
      <phone>312-227-6004</phone>
      <email>CRies@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eorna Maguire</last_name>
      <phone>617-919-1399</phone>
      <email>Eorna.Maguire@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Miller</last_name>
      <phone>212-659-1456</phone>
      <email>Catherine.miller@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mallory Rowell</last_name>
      <phone>614-722-2512</phone>
      <email>Mallory.Rowell@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Ferreira</last_name>
      <phone>267-426-1368</phone>
      <email>FERREIRAB@EMAIL.CHOP.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Baker</last_name>
      <phone>412-692-6378</phone>
      <email>Jennifer.Baker@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Bailey</last_name>
      <phone>801-587-3605</phone>
      <email>Carrie.Bailey@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PKU</keyword>
  <keyword>Phenylketonuria</keyword>
  <keyword>PAH Deficiency</keyword>
  <keyword>Hyperphenylalaninemia</keyword>
  <keyword>Phenylalanine</keyword>
  <keyword>Adeno Associated Virus</keyword>
  <keyword>AAVHSC15</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

